Millennium Management LLC Increases Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Millennium Management LLC raised its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 2,900.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 315,141 shares of the company's stock after buying an additional 304,637 shares during the period. Millennium Management LLC owned about 0.62% of Tyra Biosciences worth $4,380,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. RA Capital Management L.P. raised its holdings in shares of Tyra Biosciences by 2.1% in the 4th quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company's stock valued at $147,858,000 after purchasing an additional 220,681 shares in the last quarter. Alta Partners Management Company L.P. bought a new stake in shares of Tyra Biosciences in the 4th quarter valued at about $56,716,000. Boxer Capital Management LLC bought a new stake in shares of Tyra Biosciences in the 4th quarter valued at about $28,185,000. Janus Henderson Group PLC raised its holdings in shares of Tyra Biosciences by 63.6% in the 4th quarter. Janus Henderson Group PLC now owns 1,746,320 shares of the company's stock valued at $24,291,000 after purchasing an additional 679,124 shares in the last quarter. Finally, Farallon Capital Management LLC bought a new stake in shares of Tyra Biosciences in the 4th quarter valued at about $13,914,000. Institutional investors own 84.14% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on TYRA shares. Piper Sandler started coverage on shares of Tyra Biosciences in a research note on Wednesday, May 21st. They set an "overweight" rating and a $33.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, March 31st. Finally, Wedbush restated an "outperform" rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Friday, March 28th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $30.83.

Tyra Biosciences Trading Up 0.5%

Shares of TYRA stock traded up $0.05 during trading hours on Tuesday, hitting $9.65. The company's stock had a trading volume of 326,000 shares, compared to its average volume of 268,847. The company has a 50 day moving average of $9.25 and a 200 day moving average of $12.26. The stock has a market cap of $512.32 million, a PE ratio of -5.99 and a beta of 1.17. Tyra Biosciences, Inc. has a 12-month low of $6.42 and a 12-month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. As a group, analysts anticipate that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.